Dalotuzumab

N/A

Report date: 2025/09/01 20:01:25

Base Information

Drug NameDalotuzumab
Drug Alias NameDalotuzumabum (Pierre Fabre/MSD)达洛妥珠单抗Anti-IGF-1R monoclonal antibody (Pierre Fabre/MSD)Anti-IGF-1 receptor monoclonal antibody (Pierre Fabre/MSD)F-50-035 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPierre Fabre Group
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Frosst Canada LtdH Lee Moffitt Cancer Center & Research InstituteNational Cancer Institute +[6] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[11] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG